Artwork

Content provided by Wall Street Resource, LLC, Wall Street Resource, and LLC. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Wall Street Resource, LLC, Wall Street Resource, and LLC or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

MIRA Pharmaceuticals, Inc. Erez Aminov, CEO

14:24
 
Share
 

Manage episode 373264159 series 2612480
Content provided by Wall Street Resource, LLC, Wall Street Resource, and LLC. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Wall Street Resource, LLC, Wall Street Resource, and LLC or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

MIRA is developing a new

molecular synthetic THC analog called MIRA1a, designed for the treatment of

adult patients with anxiety and cognitive decline, typically associated with

early-stage dementia.

MIRA’s initial focus will

be a dual path: potentially winning in traditional pain and anxiety markets as

well as the marijuana analog markets with a potentially safe and effective option if approved

by the FDA.

  continue reading

150 episodes

Artwork
iconShare
 
Manage episode 373264159 series 2612480
Content provided by Wall Street Resource, LLC, Wall Street Resource, and LLC. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Wall Street Resource, LLC, Wall Street Resource, and LLC or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

MIRA is developing a new

molecular synthetic THC analog called MIRA1a, designed for the treatment of

adult patients with anxiety and cognitive decline, typically associated with

early-stage dementia.

MIRA’s initial focus will

be a dual path: potentially winning in traditional pain and anxiety markets as

well as the marijuana analog markets with a potentially safe and effective option if approved

by the FDA.

  continue reading

150 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide